BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol 2016;34:3518-28. [PMID: 27573653 DOI: 10.1200/JCO.2016.66.6693] [Cited by in Crossref: 82] [Cited by in F6Publishing: 30] [Article Influence: 16.4] [Reference Citation Analysis]
Number Citing Articles
1 He Z, Liu Q, Yang K, Chen C, Zhang X, Wang W, Zeng H, Wang B, Liu Y, Luo M, Li L, Niu Q, Lu H, Luo T, Yao X, Guo H, Ji J, Cao M, Shi Y, Ping Y, Bian X. HOXA5 is amplified in glioblastoma stem cells and promotes tumor progression by transcriptionally activating PTPRZ1. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215605] [Reference Citation Analysis]
2 Lillemoe TJ, Rendi M, Tsai ML, Knaack M, Yarosh R, Grimm E, Susnik B, Krueger J, Olet S, Swenson KK. HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Int J Breast Cancer 2021;2021:6684629. [PMID: 34123431 DOI: 10.1155/2021/6684629] [Reference Citation Analysis]
3 Yan H, Xiao H, Zhu J, Zhang J, Liu Z. Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Cancer Manag Res 2020;12:12715-22. [PMID: 33328766 DOI: 10.2147/CMAR.S278694] [Reference Citation Analysis]
4 Zhai Q, Fan J, Lin Q, Liu X, Li J, Hong R, Wang S. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS One 2019;14:e0223325. [PMID: 31584964 DOI: 10.1371/journal.pone.0223325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5 Lim TH, Lim AST, Tien SL, Tan PH. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study. Annals of Diagnostic Pathology 2022;58:151935. [DOI: 10.1016/j.anndiagpath.2022.151935] [Reference Citation Analysis]
6 Wu Y, Meng Q, Yang Z, Shi L, Hu R, Zhang P, Wei J, Ren J, Leng B, Xu D, Jiang GQ. Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer. Oncol Lett 2018;16:3726-34. [PMID: 30127983 DOI: 10.3892/ol.2018.9091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat 2021;187:95-104. [PMID: 33813685 DOI: 10.1007/s10549-021-06208-5] [Reference Citation Analysis]
8 Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, Press MF. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat 2018;172:327-38. [PMID: 30120700 DOI: 10.1007/s10549-018-4889-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
9 Gupta R, Cooper WA, Selinger C, Mahar A, Anderson L, Buckland ME, O'Toole SA. Fluorescent In Situ Hybridization in Surgical Pathology Practice. Adv Anat Pathol 2018;25:223-37. [PMID: 29727321 DOI: 10.1097/PAP.0000000000000194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Polónia A, Canelas C, Caramelo A. The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay. Virchows Arch 2022. [PMID: 35137279 DOI: 10.1007/s00428-022-03290-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
12 Kim MC, Kang SH, Choi JE, Bae YK. Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer. J Breast Cancer 2020;23:484-97. [PMID: 33154824 DOI: 10.4048/jbc.2020.23.e53] [Reference Citation Analysis]
13 Liu Y, Wu S, Shi X, Mao F, Zeng X. Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event. Front Oncol 2020;10:985. [PMID: 32637359 DOI: 10.3389/fonc.2020.00985] [Reference Citation Analysis]
14 Carpenter PM, Ziogas A, Markham EM, Cantillep AS, Yan R, Anton-Culver H. Laminin 332 expression and prognosis in breast cancer. Hum Pathol 2018;82:289-96. [PMID: 30125583 DOI: 10.1016/j.humpath.2018.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V. Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. JCO Precis Oncol 2022;6:e2100140. [PMID: 35235412 DOI: 10.1200/PO.21.00140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG. Applying the New Guidelines of HER2 Testing in Breast Cancer. Curr Oncol Rep 2020;22:51. [PMID: 32346807 DOI: 10.1007/s11912-020-0901-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Rakha EA, Miligy IM, Quinn CM, Provenzano E, Shaaban AM, Marchiò C, Toss MS, Gallagy G, Murray C, Walshe J, Katayama A, Eldib K, Badr N, Tanchel B, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Ellis IO, Lee AHS. Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases. Br J Cancer 2021;124:1836-42. [PMID: 33762723 DOI: 10.1038/s41416-021-01351-8] [Reference Citation Analysis]
18 Wang Y, Tsang JYS, Cui Y, Cui J, Lin Y, Zhao S, Law PTW, Cheung SY, Ng EKO, Tse GMK, Ke Z. Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis. Sci Rep 2017;7:6752. [PMID: 28754904 DOI: 10.1038/s41598-017-07176-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
19 Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One 2020;15:e0241775. [PMID: 33180796 DOI: 10.1371/journal.pone.0241775] [Reference Citation Analysis]
20 Adamczyk A, Kruczak A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, Domagała-Haduch M, Janecka-Widła A, Majchrzyk K, Cichocka A, Ryś J, Niemiec J. Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment. Onco Targets Ther 2018;11:4525-35. [PMID: 30122944 DOI: 10.2147/OTT.S166983] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yoder A, Inge LJ, Chen C, Marati VR, Nguyen TK, Zuiderveld K, Martin J, Gladden S, Miri MS, Venugopal R, Lopez B, Ranger-moore J, Guetter C. Computer-Aided Scoring Of () Gene Amplification Status In Breast Cancer. Journal of Pathology Informatics 2022. [DOI: 10.1016/j.jpi.2022.100116] [Reference Citation Analysis]
22 Erber R, Rübner M, Davenport S, Hauke S, Beckmann MW, Hartmann A, Häberle L, Gass P, Press MF, Fasching PA. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Res Treat 2020;184:311-24. [PMID: 32852708 DOI: 10.1007/s10549-020-05865-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Gordian-Arroyo AM, Zynger DL, Tozbikian GH. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update. Am J Clin Pathol 2019;152:17-26. [PMID: 30958889 DOI: 10.1093/ajcp/aqz012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
24 Kong H, Bai Q, Li A, Zhou X, Yang W. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline. Diagn Pathol 2022;17:5. [PMID: 34996485 DOI: 10.1186/s13000-021-01187-z] [Reference Citation Analysis]
25 Christgen M, van Luttikhuizen JL, Raap M, Braubach P, Schmidt L, Jonigk D, Feuerhake F, Lehmann U, Schlegelberger B, Kreipe HH, Steinemann D. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis. Oncotarget 2016;7:82733-40. [PMID: 27716627 DOI: 10.18632/oncotarget.12421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lin L, Sirohi D, Coleman JF, Gulbahce HE. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. Am J Clin Pathol 2019;152:479-85. [PMID: 31172196 DOI: 10.1093/ajcp/aqz061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
27 Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess 2020;24:1-190. [PMID: 32880572 DOI: 10.3310/hta24400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Qu L, Chen Q, Luo N, Zhao P, Zou Q, Mei X, Liu Z, Yi W. 3D reconstruction based novel methods are more effective than traditional clinical assessment in breast cancer axillary lymph node metastasis prediction. Sci Rep 2022;12:12425. [PMID: 35858979 DOI: 10.1038/s41598-022-16380-3] [Reference Citation Analysis]
29 Wang B, Ding W, Sun K, Wang X, Xu L, Teng X. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results. Sci Rep 2019;9:16726. [PMID: 31723206 DOI: 10.1038/s41598-019-53003-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. Am J Surg Pathol 2018;42:1190-200. [PMID: 29975246 DOI: 10.1097/PAS.0000000000001100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
31 Murray C, Flanagan L, D'Arcy C, Gullo G, Quinn CM. Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma. Virchows Arch 2020;476:367-72. [PMID: 31375912 DOI: 10.1007/s00428-019-02636-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M. Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Front Oncol 2019;9:1289. [PMID: 31850198 DOI: 10.3389/fonc.2019.01289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
33 Haskell GT, Liu YJ, Chen H, Chen B, Meyer RG, Yuhas JA, Geiersbach KB. Integrated Analysis of HER2 Copy Number by Cytogenomic Microarray in Breast Cancers With Nonclassical In Situ Hybridization Results. Am J Clin Pathol 2018;149:135-47. [PMID: 29385416 DOI: 10.1093/ajcp/aqx143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Najjar S, Allison KH. Updates on breast biomarkers. Virchows Arch 2022. [PMID: 35029776 DOI: 10.1007/s00428-022-03267-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Li J, Zhou Y, Li Y, Liu Y. Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2. Anal Cell Pathol (Amst) 2021;2021:3037993. [PMID: 34804778 DOI: 10.1155/2021/3037993] [Reference Citation Analysis]
36 Davey MG, Ryan ÉJ, Burke D, McKevitt K, McAnena PF, Kerin MJ, Lowery AJ. Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer. Breast Cancer (Auckl) 2021;15:11782234211022203. [PMID: 34177266 DOI: 10.1177/11782234211022203] [Reference Citation Analysis]
37 Sun H, Chen H, Crespo J, Tang G, Robinson M, Lim B, Şahin AA. Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy. Eur J Breast Health 2021;17:128-36. [PMID: 33870112 DOI: 10.4274/ejbh.galenos.2021.2021-2-9] [Reference Citation Analysis]
38 Blanton KC, Deal AM, Kaiser-Rogers KA, Anders CK, O'Connor SM, Hertel JD, Calhoun BC. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. Ann Diagn Pathol 2020;48:151576. [PMID: 32805517 DOI: 10.1016/j.anndiagpath.2020.151576] [Reference Citation Analysis]
39 Hwang HW, Hong SA, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Cho SY, Cho EY. Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations. Virchows Arch 2022. [PMID: 35138452 DOI: 10.1007/s00428-022-03280-0] [Reference Citation Analysis]
40 Song L, Lu H, Yin J. Preliminary study on discriminating HER2 2+ amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI. PLoS One 2020;15:e0234800. [PMID: 32555662 DOI: 10.1371/journal.pone.0234800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Geiersbach KB, Sill DR, Del Rosario KM, Meyer RG, Spears GM, Yuhas JA, Sukov WR, Jenkins RB, Ocal IT, Mounajjed T, Chen B. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results. Am J Clin Pathol 2021;156:886-94. [PMID: 33942843 DOI: 10.1093/ajcp/aqab042] [Reference Citation Analysis]
42 Agersborg S, Mixon C, Nguyen T, Aithal S, Sudarsanam S, Blocker F, Weiss L, Gasparini R, Jiang S, Chen W, Hess G, Albitar M. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification. Breast Cancer Res Treat 2018;170:321-8. [PMID: 29564742 DOI: 10.1007/s10549-018-4755-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
43 Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V. Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. NPJ Breast Cancer 2019;5:28. [PMID: 31482108 DOI: 10.1038/s41523-019-0122-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
44 Curado M, Caramelo AS, Eloy C, Polónia A. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases? Virchows Arch 2019;475:303-11. [PMID: 30953146 DOI: 10.1007/s00428-019-02567-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
45 Mohanty SK, Mishra SK, Tiwari A, Sharma S, Bhardwaj M, Pattnaik N, Jaiswal S, Baisakh MR, Das S, Pradhan MR, Swain TR, Satpathy K, Williamson SR, Parwani AV. Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines. Am J Clin Pathol 2021;156:1130-41. [PMID: 34124742 DOI: 10.1093/ajcp/aqab083] [Reference Citation Analysis]
46 Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 2019;3:PO. [PMID: 32923865 DOI: 10.1200/PO.18.00345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncol 2019;5:366-75. [PMID: 30520947 DOI: 10.1001/jamaoncol.2018.6012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
48 Li D, Weng C, Li K, Lin Q, Zhang J, Wang S, Ruan Y, Yao J. Quantification of HER2 in COS7 cells using quantum weak measurement. Opt Express 2021;29:30337-47. [PMID: 34614759 DOI: 10.1364/OE.437400] [Reference Citation Analysis]